| Homozygous Familial Hypercholesterolemia
Leqvio vs Juxtapid
Side-by-side clinical, coverage, and cost comparison for homozygous familial hypercholesterolemia.Deep comparison between: Leqvio vs Juxtapid with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsJuxtapid has a higher rate of injection site reactions vs Leqvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Juxtapid but not Leqvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Leqvio
Juxtapid
At A Glance
SC injection
Every 6 months (after initial doses)
PCSK9 siRNA
Oral
Daily
MTP inhibitor
Indications
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Homozygous Familial Hypercholesterolemia
Dosing
Hypercholesterolemia, Familial hypercholesterolemia - heterozygous, Homozygous Familial Hypercholesterolemia 284 mg SC injection initially, again at 3 months, then every 6 months; administered by a healthcare professional into abdomen, upper arm, or thigh.
Homozygous Familial Hypercholesterolemia Initiate at 5 mg once daily with water, without food, at least 2 hours after the evening meal; titrate to 10 mg after at least 2 weeks, then at minimum 4-week intervals to 20 mg, 40 mg, and up to 60 mg daily maximum; patients with ESRD on dialysis or mild hepatic impairment (Child-Pugh A) should not exceed 40 mg daily.
Contraindications
- Prior serious hypersensitivity reaction to inclisiran or any excipient in LEQVIO (including anaphylaxis and angioedema)
- Pregnancy
- Concomitant use of moderate or strong CYP3A4 inhibitors
- Moderate or severe hepatic impairment (Child-Pugh B or C) or active liver disease, including unexplained persistent elevations of serum transaminases
Adverse Reactions
Most common (>=3%) Injection site reaction, arthralgia, bronchitis
Postmarketing Anaphylaxis, angioedema, rash, pruritus, urticaria
Most common (>=28%) Diarrhea, nausea, vomiting, dyspepsia, abdominal pain
Serious Hepatotoxicity, increased ALT
Postmarketing Myalgia, alopecia
Pharmacology
PCSK9 siRNA; inclisiran is a double-stranded siRNA conjugated with GalNAc that directs catalytic breakdown of PCSK9 mRNA in hepatocytes, increasing LDL-C receptor recycling and expression on the hepatocyte cell surface to reduce circulating LDL-C.
MTP inhibitor; lomitapide directly binds and inhibits microsomal triglyceride transfer protein (MTP) in the endoplasmic reticulum, preventing assembly of apo B-containing lipoproteins in enterocytes and hepatocytes, thereby inhibiting synthesis of chylomicrons and VLDL and reducing plasma LDL-C.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Leqvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Juxtapid
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Leqvio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Juxtapid
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (5/8) · Qty limit (0/8)
Humana
Leqvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Juxtapid
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Hypercholesterolemia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Hypercholesterolemia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LeqvioView full Leqvio profile
JuxtapidView full Juxtapid profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.